文献速递肾小球疾病急性肾损伤

伴新月体形成的膜性肾小球肾炎

Membranous Glomerulonephritis With Crescents.
PubMed 文献 · Kidney Int Rep · 2019-08-13

该研究报道了15例膜性肾小球肾炎(MGN)合并坏死性新月体性肾小球肾炎(NCGN)患者的临床病理特征,其中7例ANCA阳性、5例抗GBM抗体阳性、2例抗PLA2R抗体阳性、1例抗体阴性。患者表现为大量蛋白尿、镜下血尿和急性肾损伤,均接受激素治疗,中位随访72个月时6例进展至终末期肾病、4例死亡。

要点

  • MGN合并新月体形成罕见,多与ANCA或抗GBM抗体相关。
  • 临床表现为大量蛋白尿、镜下血尿及急性肾损伤。
  • 应按急进性肾小球肾炎治疗,预后差异大。

核心结论

  • MGN伴新月体形成与ANCA或抗GBM抗体相关,是一种罕见的双重肾小球病变。
  • 患者应接受急进性肾小球肾炎的治疗方案,预后不一,40%进展至终末期肾病。

研究设计与样本

  • 回顾性队列研究,纳入15例MGN合并NCGN患者,中位年龄63岁(范围18-79),男性7例、女性8例。

主要发现

  • 12例在活检时同时诊断MGN和NCGN,3例MGN先于NCGN。
  • ANCA阳性7例(6例MPO-ANCA,1例PR3-ANCA),抗GBM抗体阳性5例,抗PLA2R抗体阳性2例,1例所有抗体阴性。
  • 除1例无尿外,所有患者均有镜下血尿;中位尿蛋白/肌酐比值为819.5 mg/mmol(范围88-5600)。
  • 新月体累及肾小球的中位比例为28%(范围5%-100%)。
  • 中位随访72个月,9例肾功能稳定或改善,6例进展至终末期肾病,4例死亡。

关键数值与推荐

  • 所有患者均接受激素治疗,10例加用环磷酰胺,6例还接受利妥昔单抗。

临床怎么用

  • 对表现为大量蛋白尿、镜下血尿和急性肾损伤的MGN患者,应警惕合并新月体病变,并按急进性肾小球肾炎积极治疗。

局限性

  • 样本量小(15例),为回顾性研究,随访时间不一,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Membranous glomerulonephritis (MGN) is rarely associated with necrotizing and crescentic glomerulonephritis (NCGN). METHODS: We report the clinical and pathologic findings in 15 patients with MGN and NCGN associated with anti-neutrophil cytoplasm antibodies (ANCAs), anti-glomerular basement membrane (GBM), or anti-phospholipase A2 receptor (PLA2R) antibodies. RESULTS: The cohort consisted of 15 patients: 7 males and 8 females with a median age of 63 years (range: 18-79). In 12 of 15 patients, MGN and NCGN were diagnosed at the time of the biopsy, and in 3 cases, MGN predated the NCGN. ANCA was positive in 7 cases (6 MPO myeloperoxidase (MPO)-ANCA and 1 PR3-ANCA), anti-GBM antibodies were detected in 5 cases, and anti-PLA2R antibodies were found in 2 cases. One case was negative for all antibodies. Microscopic hematuria was present in all but one patient who was anuric, and median urinary protein-to-creatinine ratio was 819.5 mg/mmol (range: 88-5600). Pathologic evaluation revealed MGN and NCGN with crescents involving 28% of glomeruli (median; range: 5%-100%). Follow-up was available for all 15 patients; all were treated with steroids; 10 with cyclophosphamide, and 6 also received rituximab. At a median follow-up of 72 months, 9 had stabilization or improvement of renal function, 6 had progressed to end-stage renal disease, and 4 died during the follow-up period. CONCLUSION: MGN with crescents associated with ANCAs or anti-GBM antibodies is a rare dual glomerulopathy. Patients present with heavy proteinuria, microscopic hematuria, and acute kidney injury and should be treated for a rapidly progressive glomerulonephritis. Prognosis is variable, and 40% of patients progress to end-stage renal disease.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Nikolopoulou A, Huang-Doran I, McAdoo SP, et al. Membranous Glomerulonephritis With Crescents. Kidney Int Rep. 2019. PMID: 31890999. doi:10.1016/j.ekir.2019.07.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。